Erythrodermic psoriasis improved by tildrakzumab: a case report
Erythrodermic psoriasis (EP), clinically defined as prominent erythema and scaling affecting almost the entire skin surface, is a severe form and a rare variant of psoriasis. The treatment may require hospital admission with monitoring of vital signs and use of immunosuppressive drugs. Newer biolog...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2022-07-01
|
| Series: | Dermatology Reports |
| Subjects: | |
| Online Access: | https://www.pagepress.org/journals/index.php/dr/article/view/9448 |
| _version_ | 1811225433460441088 |
|---|---|
| author | Giampaolo Trevisan Lerica Germi Luigi Naldi |
| author_facet | Giampaolo Trevisan Lerica Germi Luigi Naldi |
| author_sort | Giampaolo Trevisan |
| collection | DOAJ |
| description |
Erythrodermic psoriasis (EP), clinically defined as prominent erythema and scaling affecting almost the entire skin surface, is a severe form and a rare variant of psoriasis. The treatment may require hospital admission with monitoring of vital signs and use of immunosuppressive drugs. Newer biological drugs, including anti-TNF, anti-IL-17, and anti-IL-12/23 agents, even if not specifically developed for the treatment of erythrodermic psoriasis, have been used successfully in single cases or in small case series. Tildrakizumab is an IgG1ҡ monoclonal antibody that selectively binds to the p19 subunit thereby inhibits the interaction of interleukin 23 (IL-23) with its receptor and thus inhibits the release of IL-23 mediated proinflammatory cytokines. We present a case of EP in an obese man (Body mass index 35.2) successfully and safely treated with Tildrakizumab.
|
| first_indexed | 2024-04-12T09:06:02Z |
| format | Article |
| id | doaj.art-69b0f38cef30476f99feab6fca8e187b |
| institution | Directory Open Access Journal |
| issn | 2036-7392 2036-7406 |
| language | English |
| last_indexed | 2024-04-12T09:06:02Z |
| publishDate | 2022-07-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Dermatology Reports |
| spelling | doaj.art-69b0f38cef30476f99feab6fca8e187b2022-12-22T03:39:05ZengPAGEPress PublicationsDermatology Reports2036-73922036-74062022-07-0110.4081/dr.2022.9448Erythrodermic psoriasis improved by tildrakzumab: a case reportGiampaolo Trevisan0Lerica Germi1Luigi Naldi2Department of Dermatology, San Bortolo Hospital, VicenzaDepartment of Dermatology, San Bortolo Hospital, VicenzaDepartment of Dermatology, San Bortolo Hospital, Vicenza Erythrodermic psoriasis (EP), clinically defined as prominent erythema and scaling affecting almost the entire skin surface, is a severe form and a rare variant of psoriasis. The treatment may require hospital admission with monitoring of vital signs and use of immunosuppressive drugs. Newer biological drugs, including anti-TNF, anti-IL-17, and anti-IL-12/23 agents, even if not specifically developed for the treatment of erythrodermic psoriasis, have been used successfully in single cases or in small case series. Tildrakizumab is an IgG1ҡ monoclonal antibody that selectively binds to the p19 subunit thereby inhibits the interaction of interleukin 23 (IL-23) with its receptor and thus inhibits the release of IL-23 mediated proinflammatory cytokines. We present a case of EP in an obese man (Body mass index 35.2) successfully and safely treated with Tildrakizumab. https://www.pagepress.org/journals/index.php/dr/article/view/9448erythrodermic psoriasistreatmenttildrakizumab |
| spellingShingle | Giampaolo Trevisan Lerica Germi Luigi Naldi Erythrodermic psoriasis improved by tildrakzumab: a case report Dermatology Reports erythrodermic psoriasis treatment tildrakizumab |
| title | Erythrodermic psoriasis improved by tildrakzumab: a case report |
| title_full | Erythrodermic psoriasis improved by tildrakzumab: a case report |
| title_fullStr | Erythrodermic psoriasis improved by tildrakzumab: a case report |
| title_full_unstemmed | Erythrodermic psoriasis improved by tildrakzumab: a case report |
| title_short | Erythrodermic psoriasis improved by tildrakzumab: a case report |
| title_sort | erythrodermic psoriasis improved by tildrakzumab a case report |
| topic | erythrodermic psoriasis treatment tildrakizumab |
| url | https://www.pagepress.org/journals/index.php/dr/article/view/9448 |
| work_keys_str_mv | AT giampaolotrevisan erythrodermicpsoriasisimprovedbytildrakzumabacasereport AT lericagermi erythrodermicpsoriasisimprovedbytildrakzumabacasereport AT luiginaldi erythrodermicpsoriasisimprovedbytildrakzumabacasereport |